by Kelley Tracy | Feb 2, 2015 | Uncategorized
The Fox Chase Chemical Diversity Center is Announces it Has Been Awarded a Phase I SBIR Grant Entitled “Development of Drugs that Target the M2 Proton Channel from Influenza Virus” Doylestown, PA. February 2, 2015- FCCDC is pleased to announce that it has been...
by Kelley Tracy | Jan 23, 2015 | Uncategorized
The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase I STTR Entitled “Development of Small Molecule Therapeutics Against RNA Viruses” Doylestown, PA. January 23, 2015- FCCDC is pleased to announce that it has been awarded a Phase I STTR...
by Kelley Tracy | Dec 29, 2014 | Uncategorized
The Fox Chase Chemical Diversity Center Announces it Has Received a $100,000 Keystone Innovation Zone Tax Credit from the Department of Community & Economic Development of the Commonwealth of Pennsylvania Doylestown, PA. December 29, 2014- FCCDC is pleased to...
by Kelley Tracy | Dec 24, 2014 | Uncategorized
The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Direct to Phase II SBIR Entitled “Development of Small Molecule Therapeutics Against Smallpox and Other Poxviruses” Doylestown, PA. December 24, 2014- FCCDC is pleased to announce that it was...
by Kelley Tracy | Sep 8, 2014 | Uncategorized
The Fox Chase Chemical Diversity Center Will Be Presenting Riluzole Prodrugs to Treat ALS and Melanoma, Funded by a Phase II SBIR Grant, at the NCI SBIR Investor Forum on Nov. 13 in Santa Clara, CA Doylestown, PA. September 8, 2014- FCCDC will be presenting Riluzole...
